Acoramidis (AG10)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Amyloid Cardiomyopathy, Transthyretin-Related

Drug Information

Target Indication

Amyloid Cardiomyopathy, Transthyretin-Related

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BBOT

BridgeBio Oncology Therapeutics, Inc.

Related Pipeline

Achondroplasia

Autosomal Dominant Hypocalcemia (ADH)

Amyloidosis

Amyloid Cardiomyopathy

Idiopathic Pulmonary Fibrosis